| Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries SR Knight, CA Shaw, R Pius, TM Drake, L Norman, AO Ademuyiwa, ... The Lancet 397 (10272), 387-397, 2021 | 114 | 2021 |
| Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study SR Knight, CA Shaw, R Pius, TM Drake, L Norman, AO Ademuyiwa, ... The Lancet global health 10 (7), e1003-e1011, 2022 | 15 | 2022 |
| Dual antibiotic prophylaxis in total knee arthroplasty: where do we stand? JM Villa, TS Pannu, AM Riesgo, PD Patel, MA Mont, CA Higuera-Rueda The Journal of Knee Surgery 33 (02), 100-105, 2020 | 15 | 2020 |
| GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer AN Lisby, JC Flickinger Jr, B Bashir, M Weindorfer, S Shelukar, ... Expert review of precision medicine and drug development 6 (2), 117-129, 2021 | 9 | 2021 |
| The shifting paradigm of colorectal cancer treatment: a look into emerging cancer stem cell-directed therapeutics to lead the charge toward complete remission J Kopenhaver, M Crutcher, SA Waldman, AE Snook Expert opinion on biological therapy 21 (10), 1335-1345, 2021 | 6 | 2021 |
| Guanylyl cyclase C as a diagnostic and therapeutic target in colorectal cancer A Caspi, AA Entezari, M Crutcher, AE Snook, SA Waldman Personalized Medicine 19 (5), 457-472, 2022 | 5 | 2022 |
| Biomarkers in the development of individualized treatment regimens for colorectal cancer M Crutcher, S Waldman Frontiers in Medicine 9, 1062423, 2022 | 4 | 2022 |
| Emerging drug targets for colon cancer: A preclinical assessment MM Crutcher, TR Baybutt, JS Kopenhaver, AE Snook, SA Waldman Expert opinion on therapeutic targets 26 (3), 207-216, 2022 | 4 | 2022 |
| Dual antibiotic therapy with vancomycin and cefazolin for surgical prophylaxis in total knee arthroplasty A Cohen-Rosenblum, M Crutcher, J Gui, W Novicoff, S Nelson, J Browne Reconstructive Review 8 (2), 2018 | 4 | 2018 |
| Overview of predictive and prognostic biomarkers and their importance in developing a clinical pharmacology treatment plan in colorectal cancer patients MM Crutcher, AE Snook, SA Waldman Expert review of clinical pharmacology 15 (11), 1317-1326, 2022 | 1 | 2022 |
| 739 Development of patient-derived models of esophageal cancer for GUCY2C-directed immunotherapeutic testing M Weindorfer, A Lisby, A Zalewski, T Baybutt, R Carlson, M Crutcher, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | 1 | 2020 |
| Phase 2A trial of Ad5. F35-GUCY2C-PADRE vaccine for recurrence prevention in gastrointestinal (GI) adenocarcinomas post definitive surgery and adjuvant therapies. B Bashir, EP Mitchell, J Posey, A Basu Mallick, D Lin, R Singla, ... Journal of Clinical Oncology 42 (3_suppl), TPS235-TPS235, 2024 | | 2024 |
| Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy (PAP-UP) R Zheng, E Lam, P Altshuler, M Crutcher, H Lavu, CJ Yeo, D Stickle, ... | | 2023 |
